Select the topic
Select the Year
By integrating an risk prediction model with established staging systems like AJCC/BWH, we’ve refined risk stratification in cutaneous squamous cell carcinoma. This empowers the identification of subgroups within lower stages, enhancing personalized follow-up schedules for improved patient outcomes.
Poster presented by Dr. Yu from University Hospital Cleveland Medical Center at AAD 2024. The abstract concludes that the CP-GEP assay improved risk stratification for nodal metastasis and disease recurrence in patients with cutaneous melanoma
Delving into the intricacies of model development, insights are presented into optimizing predictive accuracy within nested case-control cohorts.
In a significant advancement, we validate risk thresholds to discern high-risk subsets across diverse cutaneous squamous cell carcinoma stages, utilizing a robust independent nationwide UK cohort. This vital research aims to refine patient stratification and improve treatment outcomes.
Delve into the intricacies of designing a discovery cohort for studying rare disease outcomes. Explore unique challenges and unveil best practices for an efficient nested case-control approach.
This study reinforces previous findings on SKY92’s prognostic value in multiple myeloma (MM). Integrating SKY92 with R-ISS enhances risk stratification, emphasizing its potential to guide personalized treatment strategies for MM patients.
Our findings validate SKY92’s efficacy in risk stratification for both progression-free survival (PFS) and overall survival (OS) in a prospective US multicenter trial. Integrating SKY92 enhances physicians’ confidence in treatment decisions by 40%.
By integrating the risk prediction model with established staging systems (AJCC/BWH), we unveil valuable insights into cutaneous squamous cell carcinoma subgroups across all stages. This enhances risk stratification, promising improved clinical decision-making and patient outcomes.
In this groundbreaking article, we unveil an absolute risk prediction model for cSCC patients, meticulously developed and rigorously validated. Leveraging routine clinical and pathological variables, it promises to revolutionize risk assessment and enhance patient care.
Multi-center US validation study unveils the potential of CP-GEP in predicting long-term survival outcomes
In the OPTIMUM (MUKnine) phase II trial, the UK consortium investigated Dara-CVRd induction followed by extended post-ASCT Dara-VRd consolidation in NDMM patients with high-risk chromosomal abnormalities and/or SKY92 high-risk status or plasma cell leukemia. This innovative approach markedly enhanced PFS compared to conventional methods.
This abstract demonstrates the effectiveness of the KiDs-GEP classifier in accurately distinguishing Kawasaki disease patients from those with other febrile illnesses within a US cohort. Additionally, it elucidates the consistent performance of the KiDs-GEP classifier across patients with complete and incomplete Kawasaki disease, offering valuable insights into its diagnostic utility, particularly in challenging diagnostic scenarios.
Independent European validation study confirming CP-GEP utility in Danish cohort. With key focus on thin melanoma achieving a SLNB reduction rate of >70% in T1’s.
This research conducts a thorough assessment of the Merlin Assay’s performance in primary cutaneous melanoma patients in the head and neck region. Our study elucidates its dual utility: predicting nodal metastases risk and long-term survival outcome.
By comparing Merlin testing to usual care, we demonstrate a path towards cost saving strategies by implementation of a novel decision-making tool in prescribing SLNB, reducing unnecessary surgeries and associated complications.
The abstract highlights significant distinctions in KiDs-GEP classifier scores between Kawasaki disease and other febrile illnesses. This suggests its potential as a valuable diagnostic tool, increasing precision and accuracy in clinical practice.
In this poster, we unveil an absolute risk prediction model for cutaneous squamous cell carcinoma.
The MERLIN_001 trial has been initiated with the aim to prospectively validate the Merlin Assay’s predictive accuracy for SLNB status and its prognostic significance in patients with melanoma who have tested negative for SLNB.
This abstract outlines the bridging of a gene signature from microarray technology to quantitative reverse transcription PCR (qRT-PCR), resulting in the development of the KiDs-GEP classifier. This adaptation achieves a more streamlined, cost-effective, and clinically viable approach, demonstrating advancement in diagnostic proficiency for hospital laboratories.
The first independent European validation study showcased the predictive power of CP-GEP in assessing disease recurrence risk in stage I/II melanoma patients, offering prospects for better prognostication in melanoma patients.
The Merlin Assay has the potential to significantly advance melanoma management by accurately identifying patients at low risk for nodal metastases, thus improving triage for surgery and limit the number of surgeries and associated complications.
This abstract outlines the transition/ bridging of a gene signature from microarray technology to quantitative reverse transcription PCR (qRT-PCR), resulting in the development of the KiDs-GEP classifier. This adaptation achieves a more streamlined, cost-effective, and clinically viable approach, demonstrating advancement in diagnostic proficiency for hospital laboratories.
This publication unveils a novel molecular classifier for PCL-like disease, boasting high sensitivity in pPCL patient detection. It identifies the molecular signature positive group in 10% of NDMM cases, offering prognostic value beyond conventional risk factors. Thus, it may present a novel diagnostic tool for identifying high-risk patients.
This study evaluated the Merlin Assay’s utility in melanoma patients with minimal sentinel node (SN) tumor burden. The study aims to determine the assay’s potential to delineate more precise prognostic profiles, thereby facilitating tailored therapeutic strategies for this specific patient subset.
This comprehensive review addresses how high-risk multiple myeloma patients can be defined. Gene expression profiling emerges as a potent tool for precise risk stratification, guiding tailored treatment for strategies of multiple myeloma patients with confidence and efficacy.
The European validation of the Merlin Assay showed a comparative analysis with established nomograms and includes a subgroup evaluation for melanoma patients aged 65 and above, increasing the understanding of its predictive performance in an elderly cohort.
We rigorously validated the SKY92 assay, establishing its credibility as a prognostic molecular test. Our meticulous approach ensures confidence in its precision and clarity.
Our study reinforces the prognostic value of GEP markers outside clinical trials. By integrating them into conventional models, we enhance risk stratification in multiple myeloma, inspiring refined prognostic strategies.
This study serves as the first independent validation in Europe, showcasing the Merlin Assay’s effectiveness, demonstrating that the process of macrodissection can be omitted during sample preparation
ProMMis, a multicenter US study, assesses SKY92’s influence on risk classification and treatment strategies. SKY92 impacted treatment decisions in 37% of patients (p < 0.001). Physicians' final risk assessments aligned with SKY92 in 89% of cases. Furthermore, SKY92 significantly bolstered physicians' confidence in treatment decisions (p < 0.001). This study underscores SKY92's potential in enhancing treatment decision-making for multiple myeloma.
An independent validation study in the United States has confirmed the Merlin Assay’s efficacy, specifically assessing its performance in the management of melanoma among patients aged 65 and older.
Our research unveils the pivotal role of SKY92 in refining prognostic accuracy of R-ISS, which was shown in multiple myeloma patients. The SKY92-R-ISS high-risk patients shows more beneficial effects from the HOVON-87/NMSG-18 trial with MPR-R with MPT-T, suggesting predictive value for treatment
Evaluating the synergistic predictive potential of combining high-risk chromosomal abnormalities and SKY92, our study unveils their predictive prowess in identifying ultra-high-risk multiple myeloma cases when a co-occurence of two or more chromosomal aberrations is found. This revelation fuels advancements in prognostic precision.
The study examines the practicality of implementing the Merlin Assay as an external laboratory test for standard patient management in the United States
The case report details the application of the Merlin Assay as a diagnostic aid for patient triage in clinical settings during the pandemic, highlighting its potential role in streamlining patient care.
This initial evaluation assesses CP-GEP’s capacity to predict recurrence risks in patients with stage I/IIA melanoma, offering new insights into disease management.
This study demonstrates the development of the CP-GEP model, also known as the Merlin Assay, designed to predict the outcomes of sentinel lymph node biopsies (SLNB) in individuals with primary cutaneous melanoma
Diagnosis of Kawasaki disease is based on clinical features and can be very challenging. This study demonstrates the identification of a 13-gene signature that is able to distinguish between Kawasaki disease and other febrile illnesses.
In a rigorous examination, eight mRNA expression signatures were tested using an independent dataset of 91 multiple myeloma patients. SKY92 emerged as the most potent predictor of survival, showcasing its potential for precise risk stratification in multiple myeloma alongside the ISS.
Through rigorous analysis spanning 4750 MM patients, our study evaluated the potency of integrating ISS, FISH markers, and gene classifiers to identify which is the best prediction model for risk classification of multiple myeloma patients. The ISS and EMC92 gene combination emerges as the strongest predictor for overall survival rate.
This publication unveils the identification of the EMC-92 gene signature, now known as SKY92, predicting the survival rate of newly diagnosed multiple myeloma patients. The signature is independently validated and independently prognostic of currently used prognostic factors.
